Published in J Infect Dis on April 03, 2012
Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev (2013) 5.78
Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev (2014) 5.14
Evaluation of tuberculosis diagnostics in children: 1. Proposed clinical case definitions for classification of intrathoracic tuberculosis disease. Consensus from an expert panel. J Infect Dis (2012) 4.60
Genome sequencing of 161 Mycobacterium tuberculosis isolates from China identifies genes and intergenic regions associated with drug resistance. Nat Genet (2013) 1.95
Transmission of multidrug-resistant tuberculosis in the USA: a cross-sectional study. Lancet Infect Dis (2013) 1.50
Systematic analysis of funding awarded for antimicrobial resistance research to institutions in the UK, 1997-2010. J Antimicrob Chemother (2013) 1.34
Mixed Mycobacterium tuberculosis complex infections and false-negative results for rifampin resistance by GeneXpert MTB/RIF are associated with poor clinical outcomes. J Clin Microbiol (2014) 1.27
Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action. Future Microbiol (2012) 1.27
Nucleic acid testing for tuberculosis at the point-of-care in high-burden countries. Expert Rev Mol Diagn (2012) 1.24
Epidemic spread of multidrug-resistant tuberculosis in Johannesburg, South Africa. J Clin Microbiol (2013) 1.20
Tuberculosis in antiretroviral treatment programs in lower income countries: availability and use of diagnostics and screening. PLoS One (2013) 1.16
Elucidating emergence and transmission of multidrug-resistant tuberculosis in treatment experienced patients by whole genome sequencing. PLoS One (2013) 1.13
Analysis of novel mycobacteriophages indicates the existence of different strategies for phage inheritance in mycobacteria. PLoS One (2013) 1.03
Extensively drug-resistant tuberculosis: epidemiology and management. Clin Epidemiol (2014) 1.02
Tuberculosis: From an incurable scourge to a curable disease - journey over a millennium. Indian J Med Res (2013) 1.01
Application of (1)h NMR spectroscopy-based metabolomics to sera of tuberculosis patients. J Proteome Res (2013) 0.89
Imperfect drug penetration leads to spatial monotherapy and rapid evolution of multidrug resistance. Proc Natl Acad Sci U S A (2015) 0.89
Patients' Experience of Tuberculosis Treatment Using Directly Observed Treatment, Short-Course (DOTS): A Qualitative Study. Iran Red Crescent Med J (2015) 0.88
Assessment of research productivity of Arab countries in the field of infectious diseases using Web of Science database. Infect Dis Poverty (2015) 0.86
Public, environmental, and occupational health research activity in Arab countries: bibliometric, citation, and collaboration analysis. Arch Public Health (2015) 0.85
In Vitro Activity of β-Lactams in Combination with β-Lactamase Inhibitors against Multidrug-Resistant Mycobacterium tuberculosis Isolates. Antimicrob Agents Chemother (2015) 0.82
Assessment of Mycobacterium tuberculosis pantothenate kinase vulnerability through target knockdown and mechanistically diverse inhibitors. Antimicrob Agents Chemother (2014) 0.80
Detection and management of drug-resistant tuberculosis in HIV-infected patients in lower-income countries. Int J Tuberc Lung Dis (2014) 0.79
Anti-tubercular therapy for intraocular tuberculosis: A systematic review and meta-analysis. Surv Ophthalmol (2016) 0.79
Are tuberculosis patients adherent to prescribed treatments in China? Results of a prospective cohort study. Infect Dis Poverty (2016) 0.78
Acquired and Transmitted Multidrug Resistant Tuberculosis: The Role of Social Determinants. PLoS One (2016) 0.77
Protein array identification of protein markers for serodiagnosis of Mycobacterium tuberculosis infection. Sci Rep (2015) 0.77
Q&A: antibiotic resistance: what more do we know and what more can we do? BMC Biol (2013) 0.76
Rapid diagnosis of MDR and XDR tuberculosis with the MeltPro TB assay in China. Sci Rep (2016) 0.76
Back to the future: a new 'old' lead for tuberculosis. EMBO Mol Med (2012) 0.76
Setting priorities for a research agenda to combat drug-resistant tuberculosis in children. Public Health Action (2015) 0.75
The Relationship between Extensively Drug-Resistant Tuberculosis and Multidrug-Resistant Gram-Negative Bacilli. PLoS One (2015) 0.75
Use of Transnational Services to Prevent Treatment Interruption in Tuberculosis-Infected Persons Who Leave the United States. Emerg Infect Dis (2016) 0.75
The within-host population dynamics of Mycobacterium tuberculosis vary with treatment efficacy. Genome Biol (2017) 0.75
Diagnostic accuracy of Xpert MTB/RIF for tuberculosis detection in different regions with different endemic burden: A systematic review and meta-analysis. PLoS One (2017) 0.75
Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS (2008) 13.25
Towards an improved investment approach for an effective response to HIV/AIDS. Lancet (2011) 11.89
Drug development for neglected diseases: a deficient market and a public-health policy failure. Lancet (2002) 11.72
Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet (2006) 10.91
An assessment of interactions between global health initiatives and country health systems. Lancet (2009) 10.53
Fluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis (2006) 9.35
Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet (2009) 7.22
HIV infection and tuberculosis in South Africa: an urgent need to escalate the public health response. Lancet (2009) 6.96
HIV status in discordant couples in sub-Saharan Africa: a systematic review and meta-analysis. Lancet Infect Dis (2010) 6.95
Expansion of cancer care and control in countries of low and middle income: a call to action. Lancet (2010) 6.84
A systematic review of task- shifting for HIV treatment and care in Africa. Hum Resour Health (2010) 6.48
Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis (2008) 5.94
Drivers of tuberculosis epidemics: the role of risk factors and social determinants. Soc Sci Med (2009) 5.93
The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med (2009) 5.78
Undiagnosed tuberculosis in a community with high HIV prevalence: implications for tuberculosis control. Am J Respir Crit Care Med (2006) 5.73
Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa. AIDS (2010) 5.46
UK investments in global infectious disease research 1997-2010: a case study. Lancet Infect Dis (2012) 5.42
Implementing antiretroviral therapy in rural communities: the Lusikisiki model of decentralized HIV/AIDS care. J Infect Dis (2007) 5.27
Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting. Am J Respir Crit Care Med (2011) 5.25
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med (2014) 5.23
Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort. AIDS (2006) 5.13
Single-dose azithromycin versus penicillin G benzathine for the treatment of early syphilis. N Engl J Med (2005) 5.05
Technologies for global health. Lancet (2012) 5.05
Prevention of mother-to-child transmission of HIV and the health-related Millennium Development Goals: time for a public health approach. Lancet (2011) 5.00
25 years of the WHO essential medicines lists: progress and challenges. Lancet (2003) 4.95
Tuberculosis. N Engl J Med (2013) 4.75
Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysis. Lancet (2006) 4.73
Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med (2012) 4.69
Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. Ann Intern Med (2011) 4.68
Sputum processing methods to improve the sensitivity of smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis (2006) 4.63
Latent Mycobacterium tuberculosis infection. N Engl J Med (2015) 4.62
Evaluation of tuberculosis diagnostics in children: 1. Proposed clinical case definitions for classification of intrathoracic tuberculosis disease. Consensus from an expert panel. J Infect Dis (2012) 4.60
HIV viral load monitoring in resource-limited regions: optional or necessary? Clin Infect Dis (2006) 4.56
The financial cost of doctors emigrating from sub-Saharan Africa: human capital analysis. BMJ (2011) 4.54
Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies. PLoS Med (2011) 4.29
Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. Clin Infect Dis (2013) 4.26
Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007-2010. Bull World Health Organ (2011) 4.19
Screening of immigrants in the UK for imported latent tuberculosis: a multicentre cohort study and cost-effectiveness analysis. Lancet Infect Dis (2011) 4.00
Health Effects of Overweight and Obesity in 195 Countries over 25 Years. N Engl J Med (2017) 3.90
The HIV-associated tuberculosis epidemic--when will we act? Lancet (2010) 3.82
Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa. Clin Infect Dis (2009) 3.77
Equity and adequacy of international donor assistance for global malaria control: an analysis of populations at risk and external funding commitments. Lancet (2010) 3.73
Mobile phone messaging for facilitating self-management of long-term illnesses. Cochrane Database Syst Rev (2012) 3.70
Vulnerability to malaria, tuberculosis, and HIV/AIDS infection and disease. Part 1: determinants operating at individual and household level. Lancet Infect Dis (2004) 3.69
Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. Lancet (2002) 3.67
Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited. Antivir Ther (2007) 3.60
Treatment of latent tuberculosis infection: a network meta-analysis. Ann Intern Med (2014) 3.57
Risk factors, barriers and facilitators for linkage to antiretroviral therapy care: a systematic review. AIDS (2012) 3.50
Linkage to HIV care and antiretroviral therapy in Cape Town, South Africa. PLoS One (2010) 3.48
Malaria: current status of control, diagnosis, treatment, and a proposed agenda for research and development. Lancet Infect Dis (2002) 3.46
Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med (2012) 3.44
Universal access to malaria medicines: innovation in financing and delivery. Lancet (2010) 3.31
The uptake and accuracy of oral kits for HIV self-testing in high HIV prevalence setting: a cross-sectional feasibility study in Blantyre, Malawi. PLoS Med (2011) 3.25
Male sex and the risk of mortality among individuals enrolled in antiretroviral therapy programs in Africa: a systematic review and meta-analysis. AIDS (2013) 3.17
Cryptococcocal immune reconstitution disease: a major cause of early mortality in a South African antiretroviral programme. AIDS (2005) 3.16
Towards universal voluntary HIV testing and counselling: a systematic review and meta-analysis of community-based approaches. PLoS Med (2013) 3.15
Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test. Lancet Infect Dis (2013) 3.12
Innovative trial designs are practical solutions for improving the treatment of tuberculosis. J Infect Dis (2012) 3.09
Quantifying and addressing losses along the continuum of care for people living with HIV infection in sub-Saharan Africa: a systematic review. J Int AIDS Soc (2012) 3.00
Distribution of antiretroviral treatment through self-forming groups of patients in Tete Province, Mozambique. J Acquir Immune Defic Syndr (2011) 2.97
Does ratification of human-rights treaties have effects on population health? Lancet (2009) 2.93
Lung diseases at necropsy in African children dying from respiratory illnesses: a descriptive necropsy study. Lancet (2002) 2.92
New and improved tuberculosis diagnostics: evidence, policy, practice, and impact. Curr Opin Pulm Med (2010) 2.92
Providing universal access to antiretroviral therapy in Thyolo, Malawi through task shifting and decentralization of HIV/AIDS care. Trop Med Int Health (2010) 2.92
Mobile phone messaging reminders for attendance at healthcare appointments. Cochrane Database Syst Rev (2012) 2.87
Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitions. Lancet Infect Dis (2010) 2.86
Operational feasibility of using loop-mediated isothermal amplification for diagnosis of pulmonary tuberculosis in microscopy centers of developing countries. J Clin Microbiol (2007) 2.85
Scaling up interventions to achieve global tuberculosis control: progress and new developments. Lancet (2012) 2.83
Clinical and molecular phenotype of Aicardi-Goutieres syndrome. Am J Hum Genet (2007) 2.81
Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries. Clin Infect Dis (2014) 2.80
Yield of HIV-associated tuberculosis during intensified case finding in resource-limited settings: a systematic review and meta-analysis. Lancet Infect Dis (2010) 2.72
Commercial serological antibody detection tests for the diagnosis of pulmonary tuberculosis: a systematic review. PLoS Med (2007) 2.71
Cryptococcal meningitis: improving access to essential antifungal medicines in resource-poor countries. Lancet Infect Dis (2013) 2.71
Role of co-trimoxazole prophylaxis in reducing mortality in HIV infected adults being treated for tuberculosis: randomised clinical trial. BMJ (2008) 2.66
Short-term risk of AIDS or death in people infected with HIV-1 before antiretroviral therapy in South Africa: a longitudinal study. Lancet (2006) 2.65
Is operational research delivering the goods? The journey to success in low-income countries. Lancet Infect Dis (2012) 2.62
Optimizing sputum smear microscopy for the diagnosis of pulmonary tuberculosis. Expert Rev Anti Infect Ther (2007) 2.62
Uptake of home-based voluntary HIV testing in sub-Saharan Africa: a systematic review and meta-analysis. PLoS Med (2012) 2.60
Global epidemiology of tuberculosis: prospects for control. Semin Respir Crit Care Med (2008) 2.57
Expanding HIV care in Africa: making men matter. Lancet (2009) 2.54
Tuberculosis incidence rates during 8 years of follow-up of an antiretroviral treatment cohort in South Africa: comparison with rates in the community. PLoS One (2012) 2.53
Prospects for tuberculosis elimination. Annu Rev Public Health (2012) 2.50
MDR tuberculosis--critical steps for prevention and control. N Engl J Med (2010) 2.49